Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia.

Trial Profile

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2016

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Apr 2014 Trial status changed to completed as reported by ClinicalTrials.gov.
    • 18 May 2012 Planned End Date changed from 1 Jun 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Planned end date changed from Jul 2010 to Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top